Sphere Medical Holding Regulatory News (SPHR)

Sphere Medical Holding plc

Sphere Medical Publishes White Paper on Anaemia, Transfusions and Blood Conservation in Critical Care

Research Highlights Potential of Proxima in Blood Conservation in ICU Patients

Cambridge, UK, 16 September 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere Medical" or the "Company") today announces the publication of a white paper exploring the issues in critical care around anaemia, transfusions and blood conservation. The white paper showed there was a 90% chance of anaemia developing in Intensive Care Unit (ICU) patients after three days with blood sampling a key contributing factor.

Dr Gavin Troughton, VP Business Development of Sphere, said: "As highlighted in our newly published white paper, transfusions are associated with poorer patient outcomes and longer stays, with subsequent cost implications. Therefore, blood conservation strategies have the potential to not only benefit patients, but also help reduce costs of care. Proxima has been specifically designed to address blood conservation strategies whilst also allowing more frequent measurement if required, therefore enabling closer monitoring of ICU patients at critical times."

Entitled 'Blood conservation with a patient dedicated arterial blood gas analyser', the new white paper is available for download from Sphere's online clinical resource centre.

- Ends -

For further information, please contact:

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.

The Company's strategy is focused on developing the Proxima (CE marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.

Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.

For further information, please visit www.spheremedical.com